EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

Brik A Kochoian iD, Cassandra Bure, Stella M Papa iD

Cells · 30.11.2023 · 12 (23) · 2754

DOI: 10.3390/cells12232754 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 30.11.2023. Verfasst von Brik A Kochoian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA. Hauptthemen laut MEDLINE: Levodopa, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NINDS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A large body of work during the past several decades has been focused on therapeutic strategies to control L-DOPA-induced dyskinesias (LIDs), common motor complications of long-term L-DOPA therapy in Parkinson’s disease (PD). Yet, LIDs remain a clinical challenge for the management of patients with advanced disease. Glutamatergic dysregulation of striatal projection neurons (SPNs) appears to be a key contributor to altered motor responses to L-DOPA. Targeting striatal hyperactivity at the glutamatergic neurotransmission level led to significant preclinical and clinical trials of a variety of antiglutamatergic agents. In fact, the only FDA-approved treatment for LIDs is amantadine, a drug with NMDAR antagonistic actions. Still, novel agents with improved pharmacological profiles are needed for LID therapy. Recently other therapeutic targets to reduce dysregulated SPN activity at the signal transduction level have emerged. In particular, mechanisms regulating the levels of cyclic nucleotides play a major role in the transduction of dopamine signals in SPNs. The phosphodiesterases (PDEs), a large family of enzymes that degrade cyclic nucleotides in a specific manner, are of special interest. We will review the research for antiglutamatergic and PDE inhibition strategies in view of the future development of novel LID therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaDyskinesia, Drug-InducedHumansPhosphoric Diester HydrolasesGlutamic AcidNucleotides, Cyclic

Stichwörter der Autor:innen

L-DOPA-induced dyskinesiaNMDARPDE10AParkinson’s diseaseglutamatephosphodiesterasestriatal projection neuron

Substanzen

LevodopaPhosphoric Diester HydrolasesGlutamic AcidNucleotides, Cyclic

Autor:innen und Institutionen

  • Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
  • Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA.

ORCID-Profile: Brik A Kochoian, Stella M Papa

Förderung

  • NIH HHS
  • NINDS NIH HHS
  • NIH
  • NIH/ORIP
  • NIH/NRSA

Zitieren

APA

Kochoian, B. A., Bure, C., & Papa, S. M. (2023). Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia. Cells, 12(23), 2754. https://doi.org/10.3390/cells12232754

Vancouver

Kochoian BA, Bure C, Papa SM. Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia. Cells. 2023;12(23):2754. doi:10.3390/cells12232754

BibTeX
@article{Kochoian2023,
  author = {Kochoian, Brik A and Bure, Cassandra and Papa, Stella M},
  title = {Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {23},
  pages = {2754},
  doi = {10.3390/cells12232754}
}
Kostenlos starten →